Ausnutria Dairy Corporation Ltd

The sale of a 35% stake in Amalthea Zuivel to A-Ware for EUR 15.78 million signals a disciplined capital reallocation strategy. Proceeds can be redeployed into higher-margin core infant formula operations, and the deal reflects management's ability to monetize non-core European dairy assets at meaningful valuations.

Divesting a 35% interest in a European cheesemaking subsidiary raises concerns about Ausnutria's long-term control over its upstream supply chain in the Netherlands. Losing influence over Amalthea could weaken vertical integration and reduce the quality assurance advantages that differentiate its premium goat-milk formula products.

With a mean analyst consensus of BUY, an average target price of 1.856 CNY versus a last close of 1.098 CNY, and a potential spread of +69.01%, analysts at firms including Huatai Research — which upgraded Ausnutria Dairy to Add with a price target of HK$2.97 — see substantial re-rating potential in the stock.

Despite the BUY consensus, the analyst coverage remains thin at only three analysts, limiting the reliability of the average target price. The wide gap between the current price and the average target may reflect deep uncertainty rather than genuine conviction, and the stock's depressed price could signal unresolved fundamental concerns.

The global infant nutrition market, valued at USD 75.64 billion in 2025 and projected to grow at a CAGR of 8%, provides a powerful structural tailwind for Ausnutria. Its recognized presence in both the global and European infant formula segments positions it to capture meaningful share of this expanding market through 2034.

Rapid market growth is attracting intensified competition, including from domestic Chinese rivals such as Junlebao Dairy launching probiotic-enriched infant formula products. As more players invest in premium and functional infant nutrition, Ausnutria faces mounting pressure on pricing power, shelf space, and brand differentiation in its key markets.